FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921136265> ?p ?o ?g. }

• W2921136265 endingPage "1199" @default.
• W2921136265 startingPage "1192" @default.
• W2921136265 abstract "Standardized uptake values (SUV), total metabolic tumor volumes (TMTV), and total lesion glycolysis (TLG) based on positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG/positron emission tomography (PET) are established outcome predictors in FDG-avid lymphomas. We therefore investigated whether these biomarkers also have prognostic value in extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma), with a focus on patients treated with anti-CD20 antibody-based immunotherapy.Pre-therapeutic [18F]FDG/PET scans of 61 treatment-naïve MALT lymphoma patients, including 35 scheduled for anti-CD20 antibody-based immunotherapy, were included in this retrospective study. SUVmean, SUVmax, TMTV, and TLG were measured and tested for 2-year progression-free survival (PFS) prognostication, using Cox regression analyses. Receiver operating characteristic curves were used to determine optimal cutoffs for prognostic [18F]FDG/PET parameters, and Kaplan-Meier estimates with log rank tests were performed.After 2 years, progression had occurred in 12/61 patients (CD20-anitbody group 6/35). TLG emerged as the only significant prognostic factor for 2-year PFS in the multivariate analyses with forward selection, both in entire cohort (hazard ratio HR, 1.001; 95 % CI, 1.001-1.002; P < 0.0001) and in the CD20-antibody group (HR, 1.001; 95 % CI, 1.001-1.002; P = 0.001). However, in the entire population, where 8/26 patients with a TLG > 90 (30.8 %) vs. 4/35 patients with a TLG ≤ 90 (11.4 %) showed progression within the 2-year observation period, TLG-based separation of risk groups failed (HR, 0.35; 95 % CI, 0.10-1.15; P = 0.069); whereas in the CD20-antibody group, where 6/16 patients with a TLG > 90 (37.5 %) vs. 0/19 patients with a TLG ≤ 90 (0.0 %) showed progression, risk group separation was successful (HR, 0.010; 95 % CI, 0.0001-8.068; P = 0.003).TLG may improve early risk stratification of MALT lymphoma patients treated with CD20-antibody-based immunotherapy." @default.
• W2921136265 created "2019-03-22" @default.
• W2921136265 creator A5004556348 @default.
• W2921136265 creator A5010019635 @default.
• W2921136265 creator A5010712142 @default.
• W2921136265 creator A5019362614 @default.
• W2921136265 creator A5034247784 @default.
• W2921136265 creator A5037080714 @default.
• W2921136265 creator A5040486048 @default.
• W2921136265 creator A5059496734 @default.
• W2921136265 creator A5082697210 @default.
• W2921136265 date "2019-03-07" @default.
• W2921136265 modified "2023-10-05" @default.
• W2921136265 title "Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy" @default.
• W2921136265 cites W1922216861 @default.
• W2921136265 cites W2051650384 @default.
• W2921136265 cites W2088783247 @default.
• W2921136265 cites W2131900456 @default.
• W2921136265 cites W2132612350 @default.
• W2921136265 cites W2148613364 @default.
• W2921136265 cites W2173762291 @default.
• W2921136265 cites W2275941472 @default.
• W2921136265 cites W2495266243 @default.
• W2921136265 cites W2507512417 @default.
• W2921136265 cites W2585649620 @default.
• W2921136265 cites W2601380568 @default.
• W2921136265 cites W2621823318 @default.
• W2921136265 cites W2737163981 @default.
• W2921136265 cites W2781993955 @default.
• W2921136265 cites W2792650805 @default.
• W2921136265 cites W2804659799 @default.
• W2921136265 cites W2806332644 @default.
• W2921136265 cites W2806838331 @default.
• W2921136265 cites W2845112623 @default.
• W2921136265 cites W2896372737 @default.
• W2921136265 doi "https://doi.org/10.1007/s11307-019-01329-2" @default.
• W2921136265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7604829" @default.
• W2921136265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30847823" @default.
• W2921136265 hasPublicationYear "2019" @default.
• W2921136265 type Work @default.
• W2921136265 sameAs 2921136265 @default.
• W2921136265 citedByCount "11" @default.
• W2921136265 countsByYear W29211362652019 @default.
• W2921136265 countsByYear W29211362652020 @default.
• W2921136265 countsByYear W29211362652021 @default.
• W2921136265 countsByYear W29211362652022 @default.
• W2921136265 crossrefType "journal-article" @default.
• W2921136265 hasAuthorship W2921136265A5004556348 @default.
• W2921136265 hasAuthorship W2921136265A5010019635 @default.
• W2921136265 hasAuthorship W2921136265A5010712142 @default.
• W2921136265 hasAuthorship W2921136265A5019362614 @default.
• W2921136265 hasAuthorship W2921136265A5034247784 @default.
• W2921136265 hasAuthorship W2921136265A5037080714 @default.
• W2921136265 hasAuthorship W2921136265A5040486048 @default.
• W2921136265 hasAuthorship W2921136265A5059496734 @default.
• W2921136265 hasAuthorship W2921136265A5082697210 @default.
• W2921136265 hasBestOaLocation W29211362651 @default.
• W2921136265 hasConcept C121608353 @default.
• W2921136265 hasConcept C126322002 @default.
• W2921136265 hasConcept C143998085 @default.
• W2921136265 hasConcept C18031839 @default.
• W2921136265 hasConcept C199374082 @default.
• W2921136265 hasConcept C207103383 @default.
• W2921136265 hasConcept C2775842073 @default.
• W2921136265 hasConcept C2776694085 @default.
• W2921136265 hasConcept C2777701055 @default.
• W2921136265 hasConcept C2779338263 @default.
• W2921136265 hasConcept C2780739268 @default.
• W2921136265 hasConcept C2908647359 @default.
• W2921136265 hasConcept C2989005 @default.
• W2921136265 hasConcept C44249647 @default.
• W2921136265 hasConcept C50382708 @default.
• W2921136265 hasConcept C71924100 @default.
• W2921136265 hasConcept C99454951 @default.
• W2921136265 hasConceptScore W2921136265C121608353 @default.
• W2921136265 hasConceptScore W2921136265C126322002 @default.
• W2921136265 hasConceptScore W2921136265C143998085 @default.
• W2921136265 hasConceptScore W2921136265C18031839 @default.
• W2921136265 hasConceptScore W2921136265C199374082 @default.
• W2921136265 hasConceptScore W2921136265C207103383 @default.
• W2921136265 hasConceptScore W2921136265C2775842073 @default.
• W2921136265 hasConceptScore W2921136265C2776694085 @default.
• W2921136265 hasConceptScore W2921136265C2777701055 @default.
• W2921136265 hasConceptScore W2921136265C2779338263 @default.
• W2921136265 hasConceptScore W2921136265C2780739268 @default.
• W2921136265 hasConceptScore W2921136265C2908647359 @default.
• W2921136265 hasConceptScore W2921136265C2989005 @default.
• W2921136265 hasConceptScore W2921136265C44249647 @default.
• W2921136265 hasConceptScore W2921136265C50382708 @default.
• W2921136265 hasConceptScore W2921136265C71924100 @default.
• W2921136265 hasConceptScore W2921136265C99454951 @default.
• W2921136265 hasFunder F4320323437 @default.
• W2921136265 hasIssue "6" @default.
• W2921136265 hasLocation W29211362651 @default.
• W2921136265 hasLocation W29211362652 @default.
• W2921136265 hasLocation W29211362653 @default.
• W2921136265 hasOpenAccess W2921136265 @default.
• W2921136265 hasPrimaryLocation W29211362651 @default.

• next